PAREA

Compass Pathways released topline data from its second Phase 3 trial of COMP360 psilocybin in treatment resistant depression. In COMP006 (n=581), two 25 mg doses showed a -3.8 MADRS difference vs 1 mg at Week 6. Prior Phase 3 data showed -3.6 vs placebo. More: tinyurl.com/readout-for-...

Spain’s Parliament hosted its first conference on psychedelic assisted psychotherapies on February 13. Clinicians, researchers, and regulators focused on evidence, responsible training, and equity in access. The debate has now formally entered the legislative arena. Learn more: tinyurl.com/spain-pap

PAREA submitted feedback on the European Commission’s ERA Act consultation, urging mental health as a strategic R&I priority and better coordinated funding that protects scientific freedom and speeds translation into practice. Learn more: parea.eu/parea-news/p...

EU institutions have agreed on the 1st major revision of pharmaceutical legislation in 20 years, reshaping incentives, access rules, and introducing regulatory sandboxes. PAREA will keep pushing for mental health to be recognised as the package moves forward. Learn more: tinyurl.com/pharma-legis...

What Europe’s health systems will require to implement psychedelic therapies — PAREA A new article published in European Neuropsychopharmacology provides a critical assessment of what psychedelic therapi es would need in order to be integrated into European healthcare systems. ...

New article maps key regulatory and clinical hurdles for bringing psychedelic therapies into EU healthcare. It underlines HTA as the decisive barrier and notes psychotherapy + pharmacotherapy as the gold standard, raising questions for assessing added value. More details: tinyurl.com/therapy-path...

PAREA will join the PSYCH Symposium in London on Dec 4. Our Project Officer, Francisca Silva, will speak on integrating psychedelic medicines into healthcare alongside the MIND Foundation, Dr Liliana Galindo and Jeff Smith MP. Learn more about the conference here: www.psychsymposium.com/agenda

The US just launched EVIDENT, a 100M mental health moonshot days after PAREA called for a mission driven mental health moonshot in Europe. Neuroplastogens included. Clear signal that mental health innovation is going strategic. Europe has a window to lead. Learn more: parea.eu/parea-news/1...

Mental health innovation is rising in Europe and PAREA is at the centre. From calling for a European Mental Health Moonshot to EU-backed psychedelic trials, new members, major policy input, and the PsyPal trial now recruiting.
Read the full newsletter: view.flodesk.com/emails/691d8...

PAREA welcomes the Women’s Brain Foundation as a new full member. Together, we’re pushing for sex and gender differences to be systematically recognised in mental health and psychedelic research, policy, and innovation across Europe.
Learn more: view.flodesk.com/emails/6911d...

PAREA is partnering with the HoloMind: Psychedelic Therapy and Integration Conference 2025, Nov 15–16 in Warsaw and online. Experts will explore how psychedelics can help treat depression, PTSD, and addiction, and how Europe can connect evidence, ethics, and practice.
holomind.org/en/2nd-editi...

We’re proud to support the first-ever Psychedelic Lived Experiences Summit! Nov 21-23| Free & Virtual
This event bridges science and lived experience to explore psychedelic healing with 50+ speakers including patients, clinicians & researchers.
🎟️ Register: psychedeliclivedexperiences.com/summit

Our Project Officer Francisca Silva will represent PAREA at IMBAS 2025 – Ireland’s leading psychedelic research conference, Oct 31–Nov 1 at Trinity College Dublin. She'll share a EU perspective on the landscape of psychedelic therapies’ development and integration in healthcare.
www.idpat.ie/events

The ALPS Awareness Lectures on Psychedelic Science return to Geneva on 24–25 October at Campus Biotech. Hosted by the ALPS Foundation, PAREA’s community supporter, the event showcases the latest expertise in psychedelic science and therapy. Learn more: www.alpsconference.com

To mark #WorldMentalHealthDay, PAREA contributed feedback to the EU’s next long-term budget. Our message: make mental health central to Europe’s innovation agenda.
We call for decisive action to ensure the next generation of mental health treatments are accessible to all who need them.

Mental health conditions cause more years of ill-health than cancer, diabetes & heart disease combined, yet innovation has stalled. Join us 4 November in Brussels & online for our hybrid event, exploring how Europe can go from lagging to leading in mental health innovation. parea.eu/events/nov4

The EMA’s updated guideline on depression treatment takes effect today, with a dedicated section on psychedelics. PAREA contributed >10 comments during consultation, many of which shaped the final text. See the revised guideline here: tinyurl.com/ema-gl

Pain Alliance Europe (PAE), has launched an important EU-wide survey exploring the links between chronic pain, mental health, and self-management. The findings will inform advocacy efforts and shape better policies for people living with chronic pain across Europe.

lnkd.in/dv2vd7CC

Buenos Aires will host LaPsyConf, an international conference on mental health, longevity, and well-being. Tadeusz Hawrot opens with Global Issues: Mental Health Indicators, Global Regulation, and Economic Impact. Get 10% off with code PAREA. Register: www.lapsyconf.com

On Oct 1 in Lisbon, following the @psypaleu.bsky.social General Assembly, PAREA will join EU at @champalimaudf.bsky.social stakeholders for a full-day symposium focused on the ethical, regulatory & clinical dimensions of psychedelic-assisted care. Learn more & register: tinyurl.com/8h2jnup

On this World Suicide Prevention Day, PAREA supports the call to change the narrative on suicide, moving from stigma and silence to openness, understanding, and support. Together, prevention is possible. @iaspinfo.bsky.social

We’re pleased to support the upcoming Borealis Psychedelic Science Summit, a two-day scientific conference taking place in Stockholm on September 26–27, as a Community Partner. Learn more and register here: borealissummit.com

The WHO just released two reports on mental health. They show more than 1B people live with a disorder, while governments’ spending has barely moved since 2017. Europe leads at $51.76 per person, the Americas just $6.86. Disorders keep rising, but investment hasn’t.
🔗 lnkd.in/dW_NU3VA

PAREA is partnering with Inawe Foundation for Psymposium Madrid 2025, Oct 2–4. The conference features leading experts in mental health, neuroscience, and psychedelics, and our community receives 10% off tickets with code PSYMP0S1UM2025. More here: tinyurl.com/parea-psympo...

The Dutch Medicines Evaluation Board will host a Pipeline Meeting on 5 Nov 2025, focusing on the regulatory development of psychedelics.

Pharmaceutical companies can apply to present and discuss psychedelic development challenges with Dutch regulators.
Deadline: 29 Aug tinyurl.com/meb-pipeline...

Norway just took a big step in mental health: its regulator will reimburse off-label generic IV ketamine for treatment-resistant depression paired with psychotherapy. Backed by a positive HTA, years of protocolized use, and NORAAD’s €2.2m study. First in Europe. More: tinyurl.com/norway-ketam...

PAREA has submitted its contribution to the EU’s EU4Health 2026 consultation. Our key message: mental health innovation must become a strategic and structural priority for EU health policy. The consultation is open until 30 September 2025. Our full contribution is available here: lnkd.in/dECfeG5d

PsyPal just enrolled its first patient in the EU’s first multi-site trial of psilocybin therapy for palliative care beyond cancer.
100+ patients, 4 sites, 1 historic step for mental health in Europe. Read the full press release here: tinyurl.com/psypal-augus...

Germany becomes the first EU country to approve compassionate use of psychedelic therapy. Patients who haven’t responded to conventional depression treatments can now access it at CIMH and the OVID Clinic. A major step toward broader access to psychedelic care in Europe! tinyurl.com/compassionat...

We’re happy to welcome Irish Doctors for Psychedelic Assisted Therapy as the newest member of PAREA’s Community Supporters network. This fall, PAREA will join the Psychedelic Research Conference, co-hosted by IDPAT and Trinity College Dublin. More here: tinyurl.com/idpat

Europe Invests in the Future of Psychedelic Science: INTEGRATE Doctoral Network Launches with €4.3 Million in Funding — PAREA A second major EU-funded project in psychedelic science, following PsyPal, will start in the coming months. INTEGRATE will be a doctoral training network supported by €4.3 million in EU funding throug...

Big news for psychedelic research in Europe:

The new €4.3M INTEGRATE project will train 16 PhDs across Europe. Funded by Marie Skłodowska-Curie Actions, it marks a major step forward. PAREA is proud to support by hosting secondments.

More here: parea.eu/parea-news/i...